[go: up one dir, main page]

WO1999038973A3 - Compounds for therapy and diagnosis of lung cancer and methods for their use - Google Patents

Compounds for therapy and diagnosis of lung cancer and methods for their use Download PDF

Info

Publication number
WO1999038973A3
WO1999038973A3 PCT/US1999/001642 US9901642W WO9938973A3 WO 1999038973 A3 WO1999038973 A3 WO 1999038973A3 US 9901642 W US9901642 W US 9901642W WO 9938973 A3 WO9938973 A3 WO 9938973A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
compounds
methods
diagnosis
therapy
Prior art date
Application number
PCT/US1999/001642
Other languages
French (fr)
Other versions
WO1999038973A2 (en
Inventor
Steven G Reed
Michael J Lodes
Tony N Frudakis
Raodoh Mohamath
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IDW20001646A priority Critical patent/ID27813A/en
Priority to CA002319117A priority patent/CA2319117A1/en
Priority to JP2000529432A priority patent/JP2002516659A/en
Priority to KR1020007008209A priority patent/KR20010034436A/en
Priority to AU23443/99A priority patent/AU2344399A/en
Priority to EP99903417A priority patent/EP1051489A2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to BR9907259-9A priority patent/BR9907259A/en
Priority to IL13741799A priority patent/IL137417A0/en
Priority to ZA9900693A priority patent/ZA99693B/en
Publication of WO1999038973A2 publication Critical patent/WO1999038973A2/en
Publication of WO1999038973A3 publication Critical patent/WO1999038973A3/en
Priority to NO20003853A priority patent/NO20003853L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compounds and methods for treating lung cancer are provided. The inventive compounds include polypeptides containing at least a portion of a lung tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of lung cancer comprising such polypeptides, or polynucleotides encoding such polypeptides, are also provided, together with polynucleotides for preparing the inventive polypeptides.
PCT/US1999/001642 1998-01-28 1999-01-26 Compounds for therapy and diagnosis of lung cancer and methods for their use WO1999038973A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IDW20001646A ID27813A (en) 1998-01-28 1999-01-20 COMPOUNDS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER AND METHODS FOR USE
JP2000529432A JP2002516659A (en) 1998-01-28 1999-01-26 Compounds for the treatment and diagnosis of lung cancer and methods of using them
KR1020007008209A KR20010034436A (en) 1998-01-28 1999-01-26 Compounds for therapy and diagnosis of lung cancer and methods for their use
AU23443/99A AU2344399A (en) 1998-01-28 1999-01-26 Compounds for therapy and diagnosis of lung cancer and methods for their use
EP99903417A EP1051489A2 (en) 1998-01-28 1999-01-26 Compounds for therapy and diagnosis of lung cancer and methods for their use
CA002319117A CA2319117A1 (en) 1998-01-28 1999-01-26 Compounds for therapy and diagnosis of lung cancer and methods for their use
BR9907259-9A BR9907259A (en) 1998-01-28 1999-01-26 Compounds for therapy and diagnosis of lung cancer and processes for their use
IL13741799A IL137417A0 (en) 1998-01-28 1999-01-26 Polypeptides containing at least a portion of a lung tumor protien and pharmaceutical compositions containing the same
ZA9900693A ZA99693B (en) 1998-01-28 1999-01-28 Compounds for therapy and diagnosis of lung cancer and methods for their use.
NO20003853A NO20003853L (en) 1998-01-28 2000-07-27 Compounds for therapy and diagnosis of lung cancer and methods for their use

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US1502998A 1998-01-28 1998-01-28
US1502298A 1998-01-28 1998-01-28
US09/015,022 1998-01-28
US09/015,029 1998-01-28
US4083198A 1998-03-18 1998-03-18
US4082898A 1998-03-18 1998-03-18
US09/040,831 1998-03-18
US09/040,828 1998-03-18
US12219198A 1998-07-23 1998-07-23
US12219298A 1998-07-23 1998-07-23
US09/122,192 1998-07-23
US09/122,191 1998-07-23
US21924598A 1998-12-22 1998-12-22
US09/219,245 1998-12-22

Publications (2)

Publication Number Publication Date
WO1999038973A2 WO1999038973A2 (en) 1999-08-05
WO1999038973A3 true WO1999038973A3 (en) 1999-12-09

Family

ID=27567530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001642 WO1999038973A2 (en) 1998-01-28 1999-01-26 Compounds for therapy and diagnosis of lung cancer and methods for their use

Country Status (13)

Country Link
EP (1) EP1051489A2 (en)
JP (1) JP2002516659A (en)
KR (1) KR20010034436A (en)
CN (1) CN1292029A (en)
AR (1) AR014514A1 (en)
AU (1) AU2344399A (en)
BR (1) BR9907259A (en)
CA (1) CA2319117A1 (en)
ID (1) ID27813A (en)
IL (1) IL137417A0 (en)
NO (1) NO20003853L (en)
WO (1) WO1999038973A2 (en)
ZA (1) ZA99693B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6518256B1 (en) 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6696247B2 (en) 1998-03-18 2004-02-24 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6821518B1 (en) 1998-03-18 2004-11-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6482597B1 (en) 1999-12-17 2002-11-19 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6312695B1 (en) 1998-03-18 2001-11-06 Corixa Corporation Compounds and methods for therapy of lung cancer
US6531315B1 (en) 1998-03-18 2003-03-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6426072B1 (en) 2000-08-02 2002-07-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
EP0987552A3 (en) 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
EP1526383A3 (en) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulfonylurea binding proteins
EP1127124A2 (en) * 1998-10-28 2001-08-29 Rigel Pharmaceuticals, Inc. Novel compositions and methods of screening for t-cell and b-cell activation modulators
EP1140137A2 (en) * 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
WO2000046370A1 (en) * 1999-02-04 2000-08-10 Board Of Trustees Of The University Of Illinois P37ing1 compositions and methods of use
US6544946B1 (en) 1999-02-19 2003-04-08 Zymogenetics, Inc. Inhibitors for use in hemostasis and immune function
PL349924A1 (en) 1999-02-19 2002-10-21 Zymogenetics Inc Inhibitors for use in hemostasis and immune function
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6759508B2 (en) 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
BR0009505A (en) * 1999-04-02 2002-06-11 Corixa Corp Lung cancer therapy and diagnosis compounds and processes
EP1187915A2 (en) * 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6509448B2 (en) 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030125245A1 (en) 1999-06-30 2003-07-03 Tongtong Wang Compositions and methods for therapy and diagnosis of lung cancer
US6914132B1 (en) 1999-06-30 2005-07-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6746846B1 (en) 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
US6667154B1 (en) 1999-06-30 2003-12-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2004500029A (en) 1999-06-30 2004-01-08 コリクサ　コーポレイション Compositions and methods for treatment and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
WO2001021653A2 (en) * 1999-09-23 2001-03-29 Corixa Corporation Ovarian tumor antigen and methods of use therefor
EP1669371A3 (en) * 1999-12-01 2006-06-21 Genentech, Inc. Composition and methods for the diagnosis of tumours
WO2001079282A2 (en) * 2000-04-14 2001-10-25 Incyte Genomics, Inc. Molecules associated with human reproduction
CA2414596A1 (en) * 2000-06-29 2002-01-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2002004514A2 (en) * 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2001270638A1 (en) * 2000-07-19 2002-01-30 Bayer Aktiengesellschaft Regulation of human airway trypsin protease-like enzyme
TWI317380B (en) * 2000-08-28 2009-11-21 Teijin Ltd Airway-specific trypsin-like enzymes and method of using the same
WO2002055694A2 (en) 2001-01-16 2002-07-18 Genset Sa Discriminative nucleic acid analysis using clone sequence signatures
US7226994B2 (en) 2001-01-18 2007-06-05 Cambridge University Technical Services Limited Cell surface expressed marker of pluripotency
GB0101300D0 (en) * 2001-01-18 2001-02-28 Univ Cambridge Tech Primordial germ cell genes
WO2003000727A2 (en) 2001-06-21 2003-01-03 Isis Innovation Limited Atopy
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2007216892B2 (en) * 2002-08-16 2011-02-10 Agensys, Inc. Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
CA2511775A1 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1,-a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
WO2006060653A2 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
ES2542141T3 (en) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Class II HLA binding WT1 peptides, and compositions and methods comprising them
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
JP2010501172A (en) * 2006-08-25 2010-01-21 オンコセラピー・サイエンス株式会社 Prognostic markers and therapeutic targets for lung cancer
EP2334826A4 (en) * 2008-09-12 2012-01-25 Cancer Res Initiative Foundation METHOD FOR DETECTION AND DIAGNOSIS OF ORAL AND RHINO-PHARYNGIAN CANCERS
CN101891802B (en) * 2009-08-11 2011-11-16 武汉凯泰新生物技术有限公司 Polypeptide or derivative product for treating or preventing cancer and application thereof
CN101921313B (en) * 2010-04-07 2012-02-29 武汉凯泰新生物技术有限公司 Polypeptide for curing or preventing cancer or derivative product and application thereof
GB201104286D0 (en) * 2011-03-15 2011-04-27 Randox Lab Ltd Glutathione S-transferase omega 1 wild type specific antibody
CN108456249B (en) * 2011-09-09 2021-09-03 转基因股份有限公司 Antibody of variant alpha-actinin-4
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2014113490A2 (en) 2013-01-15 2014-07-24 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
WO2017176769A1 (en) * 2016-04-04 2017-10-12 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
EP3541932A4 (en) * 2016-11-16 2021-03-03 The Regents of the University of California INHIBITORS OF CRISPR-CAS9
CN110669104B (en) * 2019-10-30 2021-11-05 上海交通大学 A group of markers derived from human peripheral blood mononuclear cells and their applications
CN112500467B (en) * 2020-12-14 2022-05-24 上海交通大学 Bioactive peptide RRECPSDECGAGVF, and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002552A1 (en) * 1994-07-19 1996-02-01 Cytoclonal Pharmaceutics, Inc. Lung cancer marker
WO1996030389A1 (en) * 1995-03-29 1996-10-03 Millenium Pharmaceuticals, Inc. Compositions for the diagnosis, prevention, and treatment of tumor progression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002552A1 (en) * 1994-07-19 1996-02-01 Cytoclonal Pharmaceutics, Inc. Lung cancer marker
WO1996030389A1 (en) * 1995-03-29 1996-10-03 Millenium Pharmaceuticals, Inc. Compositions for the diagnosis, prevention, and treatment of tumor progression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN S-L ET AL: "Isolation and characterizaton of a novel gene expressed in multiple cancers", ONCOGENE, vol. 12, no. 4, 15 February 1996 (1996-02-15), pages 741 - 751, XP002106655 *
YOU L ET AL.: "Identification of early growth response gene-1 (Egr-1) as a phorbol myristate-induced gene in lung cancer cells by differential mRNA display", AM. J. RESPIR. CELL MOL. BIOL., vol. 17, no. 5, November 1997 (1997-11-01), pages 617 - 624, XP002106654 *

Also Published As

Publication number Publication date
AU2344399A (en) 1999-08-16
NO20003853L (en) 2000-09-27
NO20003853D0 (en) 2000-07-27
ID27813A (en) 2001-04-26
JP2002516659A (en) 2002-06-11
BR9907259A (en) 2002-01-22
AR014514A1 (en) 2001-02-28
IL137417A0 (en) 2001-07-24
ZA99693B (en) 1999-10-21
WO1999038973A2 (en) 1999-08-05
CA2319117A1 (en) 1999-08-05
EP1051489A2 (en) 2000-11-15
KR20010034436A (en) 2001-04-25
CN1292029A (en) 2001-04-18

Similar Documents

Publication Publication Date Title
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
IL153996A0 (en) Polypeptides containing at least a portion of an ovarian carcinoma protein, polynucleotides encoding the same and pharmaceutical compositions containing the same
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
HUP0203035A2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
CA2234263A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2000061753A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO1999037775A3 (en) Compositions and methods for detecting and treating breast cancer
WO2004015390A3 (en) Lung cancer target proteins and use thereof
EP1792988A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
WO1999054466A3 (en) Colon cancer-associated antigens and their diagnostic and therapeutic uses
WO1999050289A3 (en) Transformation progression-related genes and their use
WO1999037778A3 (en) Compositions and methods for detecting and treating prostate cancer
CO5050254A1 (en) COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF CANCER DE PULMON

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99803446.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 23443/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 137417

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2319117

Country of ref document: CA

Ref document number: 2319117

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 529432

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007008209

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/007426

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999903417

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999903417

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007008209

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020007008209

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999903417

Country of ref document: EP